{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:24:39Z","timestamp":1751412279570},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:p><jats:bold>SETTING:<\/jats:bold> This was a nationwide cohort study.<jats:bold>OBJECTIVE:<\/jats:bold> To assess the treatment outcomes in patients with multidrug-resistant TB (MDR-TB) who underwent treatment guided by a national TB expert review committee in South Korea.<jats:bold>DESIGN:<\/jats:bold> We enrolled all patients\n with MDR-TB submitted for approval for the use of new TB drugs, including bedaquiline and delamanid, from 2016 to 2019. Patients were classified into two groups: those on new TB drugs and those not on new TB drugs. We compared the final treatment outcomes between the groups and analysed the\n prognostic factors.<jats:bold>RESULTS:<\/jats:bold> Of a total of 785 patients, respectively 754 (96.1%) and 31 (3.9%) were classified into the \u201cnew TB drugs\u201d group and \u201cno new TB drugs\u201d group. The new TB drugs group had a higher acid-fast bacilli smear positivity rate and higher\n resistance rate to second-line injectable drugs or fluoroquinolones. Of all the patients, 97.8% achieved culture conversion (97.7% vs. 100%), and 80.4% achieved treatment success (80.2% vs. 86.7%); there was no difference between the two groups.<jats:bold>CONCLUSIONS:<\/jats:bold> New drugs are currently\n recommended for use in all MDR-TB treatment regimens, and the use of new drugs, as determined by an expert committee, in mainly quinolone-susceptible MDR-TB, did not compromise the treatment success rate.<\/jats:p>","DOI":"10.5588\/ijtld.22.0343","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T04:35:10Z","timestamp":1673498110000},"page":"55-60","source":"Crossref","is-referenced-by-count":3,"title":["Treatment outcomes of multidrug-resistant TB with selective use of new drugs"],"prefix":"10.5588","volume":"27","author":[{"given":"Y-S.","family":"Kwon","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Chest Medicine, Masan National Tuberculosis Hospital, Masan, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-J.","family":"Yim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. S.","family":"Shim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2023\/00000027\/00000001\/art00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T04:35:24Z","timestamp":1673498124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.22.0343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"alternative-id":["1027-3719(20230101)27:1L.55;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.22.0343","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}